The European Society of Cardiology Recommends Bayer’s Xarelto (rivaroxaban) in Combination with Aspirin for the Management of Diabetes and Chronic Coronary Syndromes

The European Society of Cardiology Recommends Bayer’s Xarelto (rivaroxaban) in Combination with Aspirin for the Management of Diabetes and Chronic Coronary Syndromes

Shots:

  • The ESC has published new clinical practice guidelines to manage diabetes and CCS, replacing 2013 recommendations for the management of stable coronary artery disease and recommends Bayer’s Xarelto (2.5mg, bid) + Aspirin (qd) to treat patients with chronic coronary syndromes at high risk of further events and low risk of bleeding
  • The recommendation is based on P-III COMPASS study assessing Xarelto + Aspirin vs Aspirin as monothx. resulting in a 24% reduction in the risk of stroke, CV deaths and heart attack with 42% relative risk reduction in stroke and 18% reduction in mortality
  • Xarelto is a non-vitamin K antagonist oral anticoagulant, approved for eight indications, protecting patients for more venous and arterial thromboembolic (VAT) conditions. The guidelines also include the change in nomenclature from “stable CAD” to ‘’CCS”, reflecting the continued high risk of heart attacks, strokes and death within the patient population

Click here to­ read full press release/ article | Ref: Bayer | Image: Tamav